- Home
- SLN vs TRDA Comparison
SLN vs TRDA Comparison
Compare SLN & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- TRDA
- Stock Information
- Founded
- SLN 1994
- TRDA 2016
- Country
- SLN United Kingdom
- TRDA United States
- Employees
- SLN N/A
- TRDA 183
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- SLN Health Care
- TRDA Health Care
- Exchange
- SLN Nasdaq
- TRDA Nasdaq
- Market Cap
- SLN 273.9M
- TRDA 264.5M
- IPO Year
- SLN N/A
- TRDA 2021
- Fundamental
- Price
- SLN $6.47
- TRDA $6.71
- Analyst Decision
- SLN Buy
- TRDA Strong Buy
- Analyst Count
- SLN 5
- TRDA 3
- Target Price
- SLN $32.60
- TRDA $25.67
- AVG Volume (30 Days)
- SLN 107.6K
- TRDA 144.8K
- Earning Date
- SLN 08-14-2025
- TRDA 08-12-2025
- Dividend Yield
- SLN N/A
- TRDA N/A
- EPS Growth
- SLN N/A
- TRDA N/A
- EPS
- SLN N/A
- TRDA 0.61
- Revenue
- SLN $27,701,000.00
- TRDA $172,220,000.00
- Revenue This Year
- SLN N/A
- TRDA N/A
- Revenue Next Year
- SLN N/A
- TRDA N/A
- P/E Ratio
- SLN N/A
- TRDA $10.77
- Revenue Growth
- SLN N/A
- TRDA 5.74
- 52 Week Low
- SLN $1.97
- TRDA $6.49
- 52 Week High
- SLN $22.47
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- SLN 64.49
- TRDA 49.92
- Support Level
- SLN $5.33
- TRDA $6.87
- Resistance Level
- SLN $6.55
- TRDA $7.62
- Average True Range (ATR)
- SLN 0.44
- TRDA 0.30
- MACD
- SLN 0.02
- TRDA 0.08
- Stochastic Oscillator
- SLN 89.34
- TRDA 82.04
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.